Bioinformation 17(10): 861-865 (2021)

©Biomedical Informatics (2021)





www.bioinformation.net Volume 17(10)



Research Article

DOI: 10.6026/97320630017861

Molecular docking analysis of penta galloyl glucose with the bcl-2 family of anti-apoptotic targets

Karthick Dharmalingam¹, Velvizhi Dharmalingam², Satheesh Durairaj³, Praveen Sharma¹, Selvaraj Jayaraman⁴ & Sarita Choudhary¹

¹Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan- 342005, India; ²Department of Chemistry, Captain Srinivasa Murthy Central Ayurveda Research institute, CCRAS, Ministry of AYUSH, Government of India, Chennai – 600106; ³Department of chemistry, Siddha Central Research institute, Arumbakkam, Chennai - 600106; ⁴Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai-600 077, India Corresponding author*: Dr. Sarita Choudhary: sarita.choudhary82@gmail.com

Author contacts:

Karthick Dharmalingam - karthickgeo@gmail.com Velvizhi Dharmalingam - velvizhi727@gmail.com Satheesh Durairaj - adsatheesh@gmail.com Praveen Sharma - praveensharma55@gmail.com Selvara Jayaraman - selvarajj.sdc@saveeth.com Sarita Choudhary - sarita.choudhary82@gmail.com

Received August 10, 2021; Revised October 12, 2021; Accepted October 12, 2021, Published October 31, 2021

Declaration on official E-mail:

The corresponding author declares that official e-mail from their institution is not available for all authors

Declaration on Publication Ethics:

The authors state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Abstract:

Apoptosis requires cellular proteins from the B-cell lymphoma 2 (BCL-2) family linked to breast cancer. Therefore, it is of interest to document the Molecular docking analysis data of penta galloyl glucose with the bcl-2 family of anti-apoptotic targets (Bcl-2, BCL-XL, Caspase 3, and Caspase 9). Data shows that Pentagalloyl glucose have optimal binding features with Bcl-2, BCL-XL, Caspase 3, and Caspase 9 proteins with binding energy of -8.6,-7,-7.5 and 4.4 kcal/mol respectively for further consideration in this context.

Keywords: Breast cancer, apoptosis, penta galloyl glucose, molecular docking

Background:

Breast cancer is the most frequent cancer among women around the world. Approximately 30% of women diagnosed with early-stage

breast cancer go on to develop metastatic breast cancer, which necessitates therapy with anti-breast cancer therapeutic drugs. Although many modern anti-breast cancer medicines can slow Bioinformation 17(10): 861-865 (2021)

tumor development, the effect is usually short-lived, and patients frequently acquire resistance to the anticancer drugs utilized, resulting in about half of all treated patients relapsing [1]. This fact showed that new medicines that are more effective, safe, and have the ability to expand the lifespan of breast cancer patients are required. In multi cellular organisms, the entire process of cell division and cell death is strictly regulated. When either of these biological processes is disrupted, it has an impact on normal development and homeostasis, which can lead to cancer. Cell proliferation pathways are enhanced during cancer progression, while programmed cell death or apoptotic pathways are decreased; thus, cancer has a repertoire of these failing processes [2]. Apoptosis has been researched in a variety of processes, including normal cell turnover, embryonic development, morphogenesis, aging, cell population regulation, and tumor progression, since its commencement [3]. Although apoptosis is a frequent process for removing undesired, damaged, or hazardous cells, other mechanisms such as anoikis, necroptosis, entosis, netosis, pyroptosis, or ferroptosis are also involved in programmed cell death [4]. Extrinsic stimuli such as viral infections, xenobiotics, and pollutants can trigger apoptosis, as can intrinsic factors such as DNA damage, reactive oxygen species (ROS), and reactive nitrogen species (RNS) [5]. Apoptosis is also involved in the clearance of immune cells that have been damaged by illness or noxious substances during immunological responses [6, 7].

The B-cell lymphoma-2 (Bcl-2) family, which includes both pro- and anti-apoptotic proteins, is important in the mitochondrial pathway of apoptosis because it promotes the release of cytochrome c and Smac (Second mitochondrial-derived activator of caspases) into the cytosol, resulting in caspase-dependent cell death [8,9]. Bak and Bax, multi-domain proteins, and Bim, Bid, Puma, and Noxa, BH3 domain only proteins, are members of the Bcl-2 family of proapoptotic proteins [10]. Bcl-xl, Bcl-2, and Mcl-1 are the most wellknown anti-apoptotic proteins. The BH3-only proteins induce apoptosis via interacting with Bak and Bax or binding to antiapoptotic proteins, causing Bax and Bak to be released [11]. As a result, the ratio of anti- and pro-apoptotic proteins in the Bcl-2 family determines whether a cell lives or dies. Anti-apoptotic Bcl-2 proteins are regularly expressed in most tumor tissues and cancer cell lines [12]. Prostate cancer, breast cancer, B-cell lymphomas, and colorectal cancer, for example, all have high levels of Bcl-2. Overexpression of Bcl-2 family anti-apoptotic proteins promotes cell proliferation and survival, as well as therapeutic resistance due to apoptosis evasion. As a result, they are well-established pharmacological targets for cancer therapy. The development of anti-apoptotic protein Bcl-2 inhibitors has a lot of clinical potential. Phytochemicals, which are naturally occurring substances found in plants, are important resources for developing new medications and can also be used to treat cancer. Hence in the present study the anticancer activity of Pentagalloylglucose was identified by using insilico molecular docking analysis.

Materials and Methods Protein Preparation Three dimensional structure of BCL-2 (PDBid: 4MAN)BCL-XL: (PDB id:3ZK6), Caspase 3: (PDB id: 3GJQ), Caspase 9: (PDB id: 1NW9) were retrieved from PDB database. AutoDock Tools were used to prepare the protein structure. Water molecules and all non-standard residues have been eliminated from the basic structure. After that, all missing hydrogens and kollman charges were added to the system, and the finished protein receptor was saved as a pdbqt file and inserted immediately into PyRx's workspace folders **[13]**.

Preparation of ligand

The Pentagalloylglucose structure was downloaded from Pubchem databases in 2d SDF format. By using online smiles translator all the compounds were translated to 3d PDB format. The structures of the compounds were then loaded into PyRx and made into a ligand pdbqt file by clicking Load Molecule and create as ligand pdbqt file **[14]**.

Molecular docking

AutoDock in PyRx PyRx(0.8) GUI was used to check the binding capability of the selected antibiotics with each selected target. Docking provides valuable insight into the interaction between the proteins of with ligand. The structures of the Pentagallovlglucose were prepared before docking experiment by using make ligand command present in PyRx. Make macromolecule option was used to prepare the protein structures. AutoDock program along with the Lamarckian genetic algorithms (LGA) was used to perform docking experiments. The Lamarckian GA parameters used in the analysis consist of 30 independent runs, 150 size of population, a 25,000,000 energy evaluations, 27,000 number of generation, mutation rate of 0.02, and 0.8 crossover rate. Docking was carried out with in the pre-defined grid size for protein. For each ligand protein complex, individual docking procedures have been performed. The results were ranked in the order of increasing docking energies. The lowest binding energy of each cluster was assumed to be representative [15].

Results and Discussion

Docking experiments on Pentagalloylglucose compounds and antiapoptotic proteins were conducted. The interactions between antiapoptotic proteins and Pentagalloylglucose, as well as the binding energies of the complexes, were used to examine the AutoDock results. The accuracy of the AutoDock data was confirmed by looking at the anti-apoptotic proteins' lowest binding free energy and hydrogen bonds with penta galloyl glucose. **Table 1** shows the results of the docking analysis.

Table 1: Molecular docking results of penta galloyl glucose with selected target proteins

S. No	Protein	Binding energy	H-bond interaction
		Kcal/mol	
1	BCL-2	-8.6	PRO-120
			PHE-121
			ARG-124
			ASN-169
			TRP-173
			GLU-176
2	BCL-XL	-7	ARG-100
			ASN-136

ISSN 0973-2063 (online) 0973-8894 (print)

Bioinformation 17(10): 861-865 (2021)

			GLY-138
3	Caspase-3	-7.5	GLU-124
			LYS-137
			ARG-164
4	Caspase -9	-4.4	GLY-277
			THR-337
			SER-339
			ASP-340
			VAL-364

Docking with BCL-2

Bcl-2 was first discovered as an oncogene implicated in human B cell follicular lymphoma **[16]**. Vaux et al. found this protein's antiapoptotic action in a system where apoptosis was caused by IL-3 deficiency in 1988 **[17]**. Bcl-2 was soon found to prevent apoptosis generated by a variety of stressors, including serum deprivation, heat shock, and chemotherapeutic chemicals, implying that Bcl-2 can prevent apoptosis through a common mechanism. Certain types of necrotic cell death are also inhibited by Bcl-2. Bcl-2 was docked with Pentagalloylglucose in this study **[18]**. The binding energies with Pentagalloylglucose are used to rate the docking results. The docking simulation of BCL-2 with Pentagalloylglucose produced six hydrogen bonds with a binding energy of 8.6 kcal/mol. Table 1 and image 1 show the binding free energy (kcal/mol) for each Pentagalloylglucose interaction as well as the residues involved.

Docking with BCL-XL

JNK signaling targets Bcl-xL, a major antiapoptotic molecule. In response to microtubule inhibitors and other apoptotic stimuli like as ionizing radiation or chemotherapy, Bcl-xL is phosphorylated **[19]**. BCL-XL was chosen as one of the probable targets for molecular docking with Pentagalloylglucose in this investigation. According to the docking data, BCL-XL has a binding affinity for Pentagalloylglucose by forming three hydrogen bonds with binding energies of 7kcal/mol. It shows strong binding with bcl-xl, and the interaction of this docking is depicted in **Figure 1**.




Figure 1: Molecular interaction of pentagalloylglucose with (a) Bcl-2; (b) Bcl-xl; (c) Caspase-3 and (d) Caspase-9

©Biomedical Informatics (2021)

Docking with Caspase-3

Caspases play an important role in programmed cell death (apoptosis). Caspase-3 is a commonly activated death protease that catalyzes the selective cleavage of a variety of important cellular proteins. **Figure 1 and Table 1** demonstrate the molecular docking results of caspase 3 with Pentagalloylglucose. Pentagalloylglucose has a high affinity for caspase 3, according to the docking data. The docking results revealed that in the creation of three hydrogen bonds, interacted with binding energies of -7.5 kcal/mol.

Docking with Caspase-9

Caspases-9, the most studied initiator caspase, is a crucial component in the intrinsic or mitochondrial pathway, which is activated by a variety of stimuli including as chemotherapies, stress agents, and radiation. Caspase-9 is hypothesized to involve homodimerization monomeric zymogens and is triggered on the apoptosome complex to maintain catalytic state. Failure to activate caspase-9 has far-reaching physiological and pathophysiological consequences, including degenerative and developmental problems, as well as cancer. Caspase-9 docking studies with Pentagalloylglucose revealed an interaction with a binding energy of -4.4kcal/mol and the formation of five hydrogen bonds. All these interaction were shown in the figure 1 and the details of interaction were shown in Table 1. Docking simulation research revealed that all of the identified targets implicated in apoptotic proteins had a robust interaction behavior with Pentagalloylglucose in this investigation. It revealed that Pentagalloylglucose could be a promising anticancer candidate worthy of future investigation.

Conclusions:

Our findings show that Pentagalloylglucose have optimal binding features with Bcl-2, BCL-XL, Caspase 3, and Caspase 9 proteins with binding energy of -8.6,-7,-7.5 and 4.4 kcal/mol respectively for further consideration in this context.

Conflict of Interest:

There is no conflict of interest from any of the authors.

References:

- [1] Rivera E and Gomez H, Breast Cancer Res. 2010 12:S2. [PMID: 21050423].
- [2] Thang PM *et al.* Int J Oncol. 2016 **49:**1385. [PMID: 27499128].
- [3] Elmore S, Toxicol Pathol. 2007 35:495. [PMID: 17562483].
- [4] Cabon L et al. Med Sci (Paris). 2013 29:1117. [PMID: 24356142].
- [5] Redza-Dutordoir M et al. Biochim Biophys Acta. 2016 1863:2977. [PMID: 27646922].
- [6] Jackson SP et al. Nature. 2009 461:1071. [PMID: 19847258].
- [7] Fernald K et al. Trends Cell Biol. 2011 23:620. [PMID: 23958396]
- [8] Doi K et al. J Biol Chem. 2012 287:10224. [PMID: 22311987].
- [9] Bai L et al. Annu Rev Med. 2014 65:139. [PMID: 24188661].
- [10] Fulda S, Mitochondrion. 2013 13:195. [PMID: 22580303].
- [11] Martin LA et al. Cancer Cell. 2013 24:7 [PMID: 23845438].

ISSN 0973-2063 (online) 0973-8894 (print)

Bioinformation 17(10): 861-865 (2021)

©Biomedical Informatics (2021)

- [12] Roberts AW et al. Clin Pharmacol Ther. 2017 101:89. [PMID: 27806433].
- [13] Jayaraman S *et al. Molecules.* 2021 26:2101. [PMID: 33917607].
- [14] Selvaraj J et al. J. Biol. Act. Prod. Nat. 2020 11: 116.
- [15] Morris GM et al. J Comput Chem. 2009 30:2785. [PMID: 19399780].
- [16] Tsujimoto Y et al. Science. 1985 228:1440. [PMID: 3874430].
- [17] Vaux DL et al. Nature. 1988 335: 440. [PMID: 3262202].
- [18] Strasser A et al. Cell. 1991 67:889. [PMID: 1959134].
- [19] Upreti M et al. J Biol Chem. 2008 283:35517. [PMID: 18974096].

Edited by P Kangueane

Citation: Dharmalingam *et al.* Bioinformation 17(10): 861-865 (2021) License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article for FREE of cost without open access charges. Comments should be concise, coherent and critical in less than 1000 words. ISSN 0973-2063 (online) 0973-8894 (print) Bioinformation 17(10): 861-865 (2021)

©Biomedical Informatics (2021)

